This is the supplier profile page of Gayatri Pharma, where buyers can explore products, connect directly with the supplier for pricing inquiries.
India
3.2
46 inquiries
Add Favorite
|
Report Supplier
|
Business Description
Verify your business to unlock full company details supplier
Trade Capabilities
Business Terms
Preferred Payment Term:
Not specified
Preferred Trade Term:
Not specified
Port Of Loading:
Not specified
Accepted Currency:
USD
Trade Ability
Annual Revenue Amount:
Not specified
Numbers Of Employees:
Not specified
Avg Response Time:
≤ 7 days
Gayatri Pharma accepts USD as payment, which makes it easier for international buyers to transact without currency conversion risks. However, key trade details like staff size, revenue, compliance, response time, payment terms, trade terms, and port of origin are not specified — this limits confidence in their operational scale and reliability. Buyers should verify these missing details before placing large orders to reduce risk.
Products / Services Offered
Offering only cumin seeds means Gayatri Pharma avoids the complexity of managing diverse pharmaceutical products. This focus allows for more consistent quality control and faster delivery to buyers looking for specific spice-based ingredients. Buyers can expect reliable supply of cumin seeds without needing to source from multiple suppliers.
Main Products
Supplier Verified
Verify phone number
Verify account email
Most reliable suppliers verify their work email and business documents to confirm legitimacy, but Gayatri Pharma only has their account email and phone number verified. This means buyers can't fully confirm their official contact details or business documentation. While the phone number is verified, it doesn't replace the need for official documents or work email to validate orders or negotiate terms. Buyers should request additional verification before placing large orders or sharing sensitive information.
Export Countries
Bangladesh
Vietnam
South Asia
50%
Southeast Asia
50%
Gayatri Pharma operates in 2 countries across 2 regions, with equal exposure to South Asia and Southeast Asia at 50% each — one market in Bangladesh and one in Vietnam. This balanced regional footprint reflects a strategic approach to accessing key pharmaceutical markets in both South and Southeast Asia. The even split suggests deliberate diversification to mitigate regional risk without overcommitting to a single market.
